Long-term lung preservation with the PAF antagonist BN 52021

John Conte, Nevin M. Katz, Robert B. Wallace, Marie L. Foegh

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Platelet activating factor (PAF, l-alkyl-2(R)-acetyl- glycero-3-phosphorylcholine) is a phospholipid that is released by a variety of cells. The similarity between the pathophysiological effects of PAF and posttrans-plant pulmonary dysfunction led to an evaluation of a PAF antagonist as an adjunct to lung preservation. The ginkgolide B, BN 52021, was selected as the PAF antagonist to be studied because of the large data base available on this compound. BN 52021 was given to the donor and recipient (10 mg/kg i.v.) prior to harvest and transplantation and was included in 1 L of preservation solution (10 mg/kg) used for flushing the pulmonary artery and for storage. Left single-lung transplantation was performed following a 22-hr preservation period at 10°C. Arterial oxygen tension (pO2), pulmonary vascular resistance (PVR), alveolar arterial oxygen difference (A-aDO2), and dynamic lung compliance (DLC) were recorded for 6 hours following ligation of the native pulmonary artery. At the end of 6 hr pO2 was 243.5±61.5 vs. 71.7±10.2 mmHg (P<0.02) for the controls. A-aDO2 was less in the BN 52021 groups: 431.8±58.3 vs. 606.0±9.8 mmHg in the control groups (P<0.001), and PVR was significantly less in the BN 52021 group: 346±70.8 vs. 663±64.3 dynes/sec/cm-5 (P<0.035). We conclude that PAF antagonists like BN 52021 may be useful adjuncts for lung preservation. The effects of BN 52021 are easily explained by PAF antagonist activity in ischemic and reperfusion-induced pulmonary dysfunction. However this study does not exclude that BN 52021 may have direct effects.

Original languageEnglish (US)
Pages (from-to)1152-1156
Number of pages5
JournalTransplantation
Volume51
Issue number6
StatePublished - Jan 1 1991

Fingerprint

ginkgolide B
Lung
Vascular Resistance
Pulmonary Artery
Oxygen
Lung Compliance
Phosphorylcholine
Lung Transplantation
Platelet Activating Factor

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Conte, J., Katz, N. M., Wallace, R. B., & Foegh, M. L. (1991). Long-term lung preservation with the PAF antagonist BN 52021. Transplantation, 51(6), 1152-1156.
Conte, John ; Katz, Nevin M. ; Wallace, Robert B. ; Foegh, Marie L. / Long-term lung preservation with the PAF antagonist BN 52021. In: Transplantation. 1991 ; Vol. 51, No. 6. pp. 1152-1156.
@article{0101ced5688e48f4bcfc5a5728c1f0af,
title = "Long-term lung preservation with the PAF antagonist BN 52021",
abstract = "Platelet activating factor (PAF, l-alkyl-2(R)-acetyl- glycero-3-phosphorylcholine) is a phospholipid that is released by a variety of cells. The similarity between the pathophysiological effects of PAF and posttrans-plant pulmonary dysfunction led to an evaluation of a PAF antagonist as an adjunct to lung preservation. The ginkgolide B, BN 52021, was selected as the PAF antagonist to be studied because of the large data base available on this compound. BN 52021 was given to the donor and recipient (10 mg/kg i.v.) prior to harvest and transplantation and was included in 1 L of preservation solution (10 mg/kg) used for flushing the pulmonary artery and for storage. Left single-lung transplantation was performed following a 22-hr preservation period at 10°C. Arterial oxygen tension (pO2), pulmonary vascular resistance (PVR), alveolar arterial oxygen difference (A-aDO2), and dynamic lung compliance (DLC) were recorded for 6 hours following ligation of the native pulmonary artery. At the end of 6 hr pO2 was 243.5±61.5 vs. 71.7±10.2 mmHg (P<0.02) for the controls. A-aDO2 was less in the BN 52021 groups: 431.8±58.3 vs. 606.0±9.8 mmHg in the control groups (P<0.001), and PVR was significantly less in the BN 52021 group: 346±70.8 vs. 663±64.3 dynes/sec/cm-5 (P<0.035). We conclude that PAF antagonists like BN 52021 may be useful adjuncts for lung preservation. The effects of BN 52021 are easily explained by PAF antagonist activity in ischemic and reperfusion-induced pulmonary dysfunction. However this study does not exclude that BN 52021 may have direct effects.",
author = "John Conte and Katz, {Nevin M.} and Wallace, {Robert B.} and Foegh, {Marie L.}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "51",
pages = "1152--1156",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Conte, J, Katz, NM, Wallace, RB & Foegh, ML 1991, 'Long-term lung preservation with the PAF antagonist BN 52021', Transplantation, vol. 51, no. 6, pp. 1152-1156.

Long-term lung preservation with the PAF antagonist BN 52021. / Conte, John; Katz, Nevin M.; Wallace, Robert B.; Foegh, Marie L.

In: Transplantation, Vol. 51, No. 6, 01.01.1991, p. 1152-1156.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term lung preservation with the PAF antagonist BN 52021

AU - Conte, John

AU - Katz, Nevin M.

AU - Wallace, Robert B.

AU - Foegh, Marie L.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Platelet activating factor (PAF, l-alkyl-2(R)-acetyl- glycero-3-phosphorylcholine) is a phospholipid that is released by a variety of cells. The similarity between the pathophysiological effects of PAF and posttrans-plant pulmonary dysfunction led to an evaluation of a PAF antagonist as an adjunct to lung preservation. The ginkgolide B, BN 52021, was selected as the PAF antagonist to be studied because of the large data base available on this compound. BN 52021 was given to the donor and recipient (10 mg/kg i.v.) prior to harvest and transplantation and was included in 1 L of preservation solution (10 mg/kg) used for flushing the pulmonary artery and for storage. Left single-lung transplantation was performed following a 22-hr preservation period at 10°C. Arterial oxygen tension (pO2), pulmonary vascular resistance (PVR), alveolar arterial oxygen difference (A-aDO2), and dynamic lung compliance (DLC) were recorded for 6 hours following ligation of the native pulmonary artery. At the end of 6 hr pO2 was 243.5±61.5 vs. 71.7±10.2 mmHg (P<0.02) for the controls. A-aDO2 was less in the BN 52021 groups: 431.8±58.3 vs. 606.0±9.8 mmHg in the control groups (P<0.001), and PVR was significantly less in the BN 52021 group: 346±70.8 vs. 663±64.3 dynes/sec/cm-5 (P<0.035). We conclude that PAF antagonists like BN 52021 may be useful adjuncts for lung preservation. The effects of BN 52021 are easily explained by PAF antagonist activity in ischemic and reperfusion-induced pulmonary dysfunction. However this study does not exclude that BN 52021 may have direct effects.

AB - Platelet activating factor (PAF, l-alkyl-2(R)-acetyl- glycero-3-phosphorylcholine) is a phospholipid that is released by a variety of cells. The similarity between the pathophysiological effects of PAF and posttrans-plant pulmonary dysfunction led to an evaluation of a PAF antagonist as an adjunct to lung preservation. The ginkgolide B, BN 52021, was selected as the PAF antagonist to be studied because of the large data base available on this compound. BN 52021 was given to the donor and recipient (10 mg/kg i.v.) prior to harvest and transplantation and was included in 1 L of preservation solution (10 mg/kg) used for flushing the pulmonary artery and for storage. Left single-lung transplantation was performed following a 22-hr preservation period at 10°C. Arterial oxygen tension (pO2), pulmonary vascular resistance (PVR), alveolar arterial oxygen difference (A-aDO2), and dynamic lung compliance (DLC) were recorded for 6 hours following ligation of the native pulmonary artery. At the end of 6 hr pO2 was 243.5±61.5 vs. 71.7±10.2 mmHg (P<0.02) for the controls. A-aDO2 was less in the BN 52021 groups: 431.8±58.3 vs. 606.0±9.8 mmHg in the control groups (P<0.001), and PVR was significantly less in the BN 52021 group: 346±70.8 vs. 663±64.3 dynes/sec/cm-5 (P<0.035). We conclude that PAF antagonists like BN 52021 may be useful adjuncts for lung preservation. The effects of BN 52021 are easily explained by PAF antagonist activity in ischemic and reperfusion-induced pulmonary dysfunction. However this study does not exclude that BN 52021 may have direct effects.

UR - http://www.scopus.com/inward/record.url?scp=0025881585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025881585&partnerID=8YFLogxK

M3 - Article

C2 - 2048190

AN - SCOPUS:0025881585

VL - 51

SP - 1152

EP - 1156

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 6

ER -

Conte J, Katz NM, Wallace RB, Foegh ML. Long-term lung preservation with the PAF antagonist BN 52021. Transplantation. 1991 Jan 1;51(6):1152-1156.